DUBLIN: Research and Markets, the world's leading source for international market research reports and data, has seen a surge in demand for its services from pharmaceutical and healthcare companies, as the sector grapples with the disruptive pace of artificial intelligence (AI), regulatory shifts, and an overwhelming volume of market information.

With more than 650 publishing partners, Research and Markets stands apart as a trusted advocate for its clients. It helps global pharmaceutical companies navigate a fragmented, often confusing research landscape and make informed decisions with confidence. In a time when questions around quality, trust, and bias are front and centre, the company’s independent, client-first model is proving more valuable than ever.

“We’re not here to push a particular publisher. We’re here to help our clients find the intelligence that best suits their needs, whether that’s a global forecast from a top-tier provider or a specialist report from a niche supplier that’s hard to access anywhere else,” said Ross Glover, CEO of Research and Markets. “It’s about independence, experience, and a relentless focus on quality.”

From multinational pharmaceutical companies to emerging biotech firms, Research and Markets supports a broad range of organisations across the healthcare and life sciences sectors. Clients include leading drug manufacturers, contract research and manufacturing organisations, and healthcare-focused investors, all of whom rely on timely, credible market intelligence to guide strategy, innovation, and investment decisions.

Within those organisations, the platform is relied upon by a wide array of roles, including:

• Heads of Competitive Intelligence
• Directors of Market Research
• R&D and Pipeline Strategy Leads
• Corporate Librarians
• Business Development Executives
• Commercial and Marketing Directors
• Medical Affairs Managers
• Procurement and Vendor Management Professionals

Beyond providing access to a vast catalogue of research, Research and Markets also simplifies the procurement process. Clients benefit from a single point of access to hundreds of suppliers, reducing friction for purchasing teams, streamlining internal workflows, and ensuring compliance with procurement policies. This is particularly important for large, global organisations managing multiple business units and complex research needs.

“Procurement teams love that they don’t need to onboard dozens of niche suppliers individually,” said Glover. “With us, they have one contract, one relationship, and access to everything from mainstream to highly specialised intelligence.”

Key topics currently driving demand include:

• AI in Drug Discovery and Development
• Digital Therapeutics and Remote Patient Monitoring
• CDMO and CRO Market Trends
• Personalised Medicine and Genomics
• Cell and Gene Therapy Pipelines
• Regulatory Intelligence and Market Access
• Rare Disease and Orphan Drug Development

“Our role is to be a partner in progress,” added Glover. “We don’t just help clients buy research. We help them buy well. We understand the space, we know the sources, and we work hard every day to match organisations with insights that actually move their strategy forward.”

Fonte: Business Wire